Drug Trial Radar · NCT07390864
Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy
Last checked: Nov 20, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jan 18, 2026
Primary completion
Jul 30, 2026
Study completion Aug 30, 2026
Sponsor
- Lead sponsor
- Cairo UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kafrelsheikh University
- First posted
- Feb 5, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 25 years, up to 48 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this randomized clinical trial is to determine whether intramyometrial ergometrine injection or intramyometrial carbetocin injection is more effective in reducing blood loss during and after abdominal myomectomy in women undergoing surgery for symptomatic uterine fibroids. The main questions it aims to answer are: Does intramyometrial ergometrine reduce intraoperative and postoperative blood loss during abdominal myomectomy? Does intramyometrial carbetocin reduce intraoperative and postoperative blood loss during abdominal myomectomy? Is there a difference between the two drugs in the need for blood transfusion and postoperative hemoglobin drop? Researchers will compare intramyometrial ergometrine injection with intramyometrial carbetocin injection to see which intervention is more effective in controlling surgical bleeding and improving surgical outcomes. Participants will: Undergo abdominal myomectomy for uterine fibroids Receive either intramyometrial ergometrine or intramyometrial carbetocin during surgery Be monitored for intraoperative blood loss, postoperative blood loss, hemoglobin changes, and need for blood transfusion
Conditions
- Myoma;Uterus
Interventions
Methylergometrine (Intramyometrial Injection)Drug
Methylergometrine maleate is administered as an intramyometrial injection diluted in normal saline and injected circumferentially around the myoma before uterine incision during abdominal myomectomy to induce sustained uterine contraction and reduce surgical blood loss.
Carbetocin (Intramyometrial Injection)Drug
Carbetocin is administered as an intramyometrial injection diluted in normal saline and injected circumferentially around the myoma before uterine incision during abdominal myomectomy to promote sustained uterine contraction and reduce intraoperative and postoperative blood loss.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimated Intraoperative and Postoperative Blood LossTime frame: From the start of surgery until removal of the intraperitoneal drain (up to 48 hours postoperatively)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fayoum University
Al Fayyum, Faiyum Governorate, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.